Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $48.00 target price on the stock. BTIG Research‘s price target suggests a potential upside of 267.25% from the company’s previous close.
Several other research firms also recently weighed in on AAPG. Citizens Jmp started coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective on the stock. William Blair began coverage on Ascentage Pharma Group International in a report on Friday, October 16th. They issued an “outperform” rating for the company. Citigroup began coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 target price for the company. Finally, JPMorgan Chase & Co. dropped their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research report on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $43.44.
View Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Trading Down 0.5%
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. On average, equities analysts anticipate that Ascentage Pharma Group International will post -2.43 earnings per share for the current year.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
See Also
- Five stocks we like better than Ascentage Pharma Group International
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
